NKGen Biotech Reports $15.4 Million Net Income Turnaround and FDA Clearance for Alzheimer’s Therapy

NKGen Biotech, Inc. has reported significant financial developments in its latest 10-Q filing for the quarter ending March 31, 2025. The company recorded a net income of $15.4 million, a notable turnaround from a net loss of $5.4 million during the same period in 2024. This improvement is attributed to a substantial increase in other income, primarily from changes in the fair value of financial instruments, which amounted to $21.6 million, compared to $3.8 million in the previous year. Total expenses for the quarter decreased to $4.7 million from $7.6 million, driven by reductions in both research and development (R&D) and general and administrative (G&A) expenses.

In terms of operational changes, NKGen has made strategic moves to streamline its operations. R&D expenses fell by 43% to $1.9 million, reflecting a focus on advancing its Alzheimer’s disease (AD) trials while reducing costs associated with other indications. G&A expenses also decreased by 36% to $2.8 million, largely due to lower professional fees and stock option expenses. The company’s total liabilities decreased to $66.2 million from $86.1 million, primarily due to a reduction in convertible promissory notes and other financial instruments.

NKGen has also made significant strides in its clinical development efforts. The company received investigational new drug (IND) clearance from the FDA for its SNK01 therapy targeting Alzheimer’s disease and has initiated clinical trials. The company aims to expand its pipeline and is actively pursuing collaborations to enhance its product development capabilities. As of March 31, 2025, NKGen had 51.3 million shares of common stock outstanding, reflecting an increase from 44.2 million shares at the end of 2024.

Looking ahead, NKGen faces challenges related to its liquidity and ongoing operational costs. The company reported a working capital deficit of approximately $41.5 million and expressed substantial doubt about its ability to continue as a going concern without securing additional funding. Management indicated that it will need to raise capital through equity or debt financing to support its operations and product development initiatives. The company is actively exploring various financing options, including potential collaborations and grants, to ensure it can meet its financial obligations and continue its clinical programs.